COVID-19 Healthcare Provider Information

Important Information for Providers
Updated March 26 at 1:00 p.m.

Please review our COVID-19 information sheet with test and collection information (updated 3.26.20).

View the DLO Healthcare Provider COVID-19 information sheet (updated 3.26.20)

There are multiple collection devices that can be used for COVID-19 testing. DLO's preferred devices are the Nasopharyngeal and/or Oropharyngeal swab collected in a multi microbe media (M4) VCM, medium (green-cap) tube or equivalent (UTM). For a complete list of other acceptable collection devices, please view DLO's Specimen Collection Device Guidelines.

View the DLO Specimen Collection Device Guidelines (updated 3.26.20)

To meet the growing demand of our healthcare providers and patients, DLO and Quest Diagnostics have been rapidly expanding testing capacity by adding:

  • Test Code 39433: The Quest Diagnostics lab-developed test (LDT) to many of its other high-complexity laboratories including Chantilly, VA and Marlborough, MA. This test has been authorized by FDA under an EUA for use by authorized laboratories.
  • Test Code 39444: A high-throughput, FDA-Emergency Use Authorized Roche Diagnostics test for COVID-19, which is now available.
  • With the Roche test now available broadly, customers should be ordering the Roche test when submitting upper respiratory specimens. The Roche platform provides high-throughput automation, which will enable us to provide more testing capacity. For lower respiratory specimens, including bronchial lavage/wash (BAL), nasopharyngeal aspirate/wash, tracheal aspirate, or sputum, customers can still must order the LDT (test code 39433) for those specimen types.
  • Both tests codes available can utilize the nasopharyngeal (preferred) and/or oropharyngeal specimen types.

View the COVID-19 HCP Fact Sheet - Roche

View the COVID-19 HCP Fact Sheet - Quest LDT

Providers should not refer any patients suspected (persons under investigation) or confirmed to be infected with COVID-19 to a DLO Patient Service Center or other phlebotomy site.

DLO will continue to provide test services for patients suspected (persons of interest) specimens collected in appropriate healthcare settings, such as physician offices and hospitals.

Providers should review the CDC website or contact their public health authority for information to guide their patient management and lab testing for COVID-19.

This is a changing situation and we will provide updates as our plans develop.


What is Coronavirus Disease 2019?
Coronavirus Disease 2019 or COVID-19 (formally known as 2019-nCoV) is the name for the respiratory syndrome caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

When did DLO begin to offer testing for COVID-19?
DLO began to provide testing for COVID-19 on March 10, 2020.

What is the name of the test?
SARS-CoV-2 RNA, Qualitative Real-Time RT-PCR.

How does the test work?
The DLO SARS-CoV-2 RNA, Qualitative Real-Time RT-PCR aids the confirmatory detection of nucleic acid in respiratory specimens of patients meeting the clinical criteria of the U.S. Centers for Disease Control and Prevention (CDC) for COVID-19 testing.

Where is the test performed?
The test was developed, validated and now performed at our Quest Diagnostics Infectious Disease laboratory in San Juan Capistrano, California. Quest has expanded testing to additional high-complexity Quest Diagnostics laboratories, including their lab in the Dallas area.

How fast will doctors get results back?
We expect results to be available 3-4 days from the time of specimen pickup; however, timing may be impacted by high demand.

Is the test approved by the Food and Drug Administration (FDA)?
The test has not been FDA cleared or approved or authorized. The test has been validated according to CLIA (Clinical Laboratory Improvement Amendments), but FDA’s independent review of this validation is pending.

Does DLO collect specimens from persons under investigation (PUI) for COVID-19 or with confirmed COVID-19 at its Patient Service Center or other phlebotomy sites?
No. DLO does not collect, process or transport specimens from PUI or patients confirmed with COVID-19 at our Patient Service Centers or other phlebotomy sites.

Will DLO perform standard diagnostics testing (non-COVID-19) for PUI and confirmed COVID-19 patients using specimens collected in non-Quest Diagnostics settings, such as physician offices or hospitals?
Yes. Specimens collected at physician offices, clinics or hospital settings may be forwarded per normal logistics processes to DLO.

Can patients order this directly, such as through DLO Direct?
No. A physician must order the test for a patient.

Are masks or other personal protective equipment available for visitors to DLO locations?
Patients meeting established criteria will be offered a face mask. Current guidance does not support general use of masks or personal protective equipment for the public. We encourage individuals to visit the CDC website for more information.

Helpful Coronavirus Links

Still have questions?

For answers to more questions about COVID-19, healthcare providers and patients are welcome to call 866-404-1550, the national call center provided by Quest Diagnostics. This call center can provide answers to many questions, but they cannot provide answers regarding patient results.